Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants

Title:Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants

Volume: 15 Issue: 4

Author(s): Hubertus Himmerich, Juliane Minkwitz and Kenneth C. Kirkby

Affiliation:

Keywords: Antidepressants, antipsychotics, glucose metabolism, obesity, weight gain.

Abstract: Weight gain and metabolic disturbances are common side effects during psychopharmacological treatment with specific antipsychotics and antidepressants. The antipsychotics clozapine and olanzapine, and antidepressants tricyclics and mirtazapine have a high risk of inducing weight gain.

Recently discovered pathophysiological mechanisms include antihistaminergic effects, activation of hypothalamic adenosine monophosphate-activated protein kinase (AMPK), modulation of hormonal signaling of ghrelin and leptin, changes in the production of cytokines such as tumor necrosis factor-alpha (TNF)-alpha and adipokines such as adiponektin, and the impact of genes, in particular the melanocortin 4 receptor (MC4R), serotonin 2C receptor (HTR2C), leptin, neuropeptide Y (NPY) and cannabinoid receptor 1 (CNR1) genes.

Metabolic changes associated with weight gain include disturbances of glucose and lipid metabolism. Clozapine and olanzapine may, in addition to mechanisms resulting from weight gain, impair glucose metabolism by blockade of the muscarinic M3 receptor (M3R). Antidepressants associated with weight gain appear to have fewer unfavourable effects on glucose and lipid metabolism than the second-generation antipsychotics clozapine and olanzapine.

To assess the risk of weight gain and its consequences for the patient’s health, assessing body weight changes and metabolic monitoring in the first week of treatment as well as in long-term treatment is recommended.

Cite this article as:

Himmerich Hubertus, Minkwitz Juliane and Kirkby C. Kenneth, Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (4) . https://dx.doi.org/10.2174/1871530315666150623092031